Vertex Pharmaceuticals Stock News

Baker Tilly Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,691 shares of the pharmaceutical companys stock, valued at approximately $1,214,000. Several other hedge funds have []

Waldron Private Wealth LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,555 shares of the pharmaceutical companys stock after acquiring an additional 346 shares during the period. Waldron Private []

Parallel Advisors LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,452 shares of the pharmaceutical companys stock after purchasing an additional 115 shares during the period. Parallel Advisors []

Asset Management One Co. Ltd. lowered its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 156,940 shares of the pharmaceutical company’s stock after selling 5,381 shares during the period. Asset Management One Co. […]

Commonwealth Equity Services LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 74,791 shares of the pharmaceutical companys stock after acquiring an additional 9,820 shares during the period. Commonwealth Equity Services LLCs holdings in Vertex []

Signaturefd LLC reduced its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 49.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,676 shares of the pharmaceutical companys stock after selling 1,636 shares during the quarter. Signaturefd LLCs holdings in Vertex Pharmaceuticals were worth $304,000 at the []

VRTX's legacy business is valued at $279 per share. Despite the VX-814 and VX-864 failures, Vertex's pipeline looks solid and promising.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $215.41, moving +0.41% from the previous trading session.

AMG National Trust Bank bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,154 shares of the pharmaceutical companys stock, valued at approximately $572,000. Several other hedge funds and other institutional investors have []

Wolff Wiese Magana LLC lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 37.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,661 shares of the pharmaceutical companys stock after selling 3,351 shares during the period. Wolff Wiese Magana LLCs holdings in Vertex Pharmaceuticals []

TheStreet upgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from a c+ rating to a b- rating in a report issued on Thursday, TheStreetRatingsTable reports. A number of other research analysts have also issued reports on VRTX. Wells Fargo & Company started coverage on shares of Vertex Pharmaceuticals in a research note on Wednesday, December 8th. They []

These stocks have been beaten down in 2021. But their prospects remain bright.

They could be like PCs in the 1980s and the internet in the 1990s.

Texas Permanent School Fund lessened its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,078 shares of the pharmaceutical companys stock after selling 2,927 shares during the quarter. Texas Permanent School Funds holdings []

Huntington National Bank lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,313 shares of the pharmaceutical companys stock after selling 441 shares during the quarter. Huntington National Banks holdings in []